Figure 6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer

Evaluating the toxicity of ZSTK3744 in vivo. A, Representative hematoxylin and eosin staining images of rat lung, liver, and kidney following daily intravenous treatment with vehicle or ZSTK3744 (50 mg/kg) for four consecutive days. These images were analyzed to assess histologic changes associated with potential toxicity. B, Representative hematoxylin and eosin staining images of dog liver and lungs after intravenous administration of 0.38, 0.96, 2.4, 6, and 15 mg/kg (7.68, 19.2, 48, 120, and 300 mg/m2) of ZSTK3744 on days 0, 7, 14, 21, and 28, respectively. Seven days after the final administration, the lungs and liver of the dogs were histopathologically examined.